These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 33574756)

  • 41. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapeutic approaches to curtail COVID-19.
    Owji H; Negahdaripour M; Hajighahramani N
    Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment.
    Zawilska JB; Lagodzinski A; Berezinska M
    J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 34987123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Insight Into COVID-19: A 21st Century Disaster and Its Relation to Immunocompetence and Food Antioxidants.
    Siddique F; Abbas RZ; Mansoor MK; Alghamdi ES; Saeed M; Ayaz MM; Rahman M; Mahmood MS; Iqbal A; Manzoor M; Abbas A; Javaid A; Hussain I
    Front Vet Sci; 2020; 7():586637. PubMed ID: 33521076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Comparative Study on Virology, Epidemiology, and Clinical Features of SARS and COVID-19.
    Zhao Y; Lu Q; Meng X; Huang S; Zhang J; Dong W; Fan H; Hou S
    Disaster Med Public Health Prep; 2021 Aug; 17():e35. PubMed ID: 34462042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV.
    Meo SA; Alhowikan AM; Al-Khlaiwi T; Meo IM; Halepoto DM; Iqbal M; Usmani AM; Hajjar W; Ahmed N
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):2012-2019. PubMed ID: 32141570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Challenges in an Outbreak of COVID-19 in Wuhan, China: Concerns from Frontiers.
    Wang Y; Wang L; Li X; Gong Z
    Curr Infect Dis Rep; 2020; 22(11):30. PubMed ID: 32982600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.
    Bhatti JS; Bhatti GK; Khullar N; Reddy AP; Reddy PH
    Mol Neurobiol; 2020 Nov; 57(11):4856-4877. PubMed ID: 32808122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coronavirus disease 2019: A new severe acute respiratory syndrome from Wuhan in China.
    Cao Y; Cai K; Xiong L
    Acta Virol; 2020; 64(2):245-250. PubMed ID: 32551792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.
    Muralidar S; Ambi SV; Sekaran S; Krishnan UM
    Biochimie; 2020 Dec; 179():85-100. PubMed ID: 32971147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Animal Models of COVID-19: Transgenic Mouse Model.
    Park JG; Pino PA; Akhter A; Alvarez X; Torrelles JB; Martinez-Sobrido L
    Methods Mol Biol; 2022; 2452():259-289. PubMed ID: 35554912
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of Big Data and Artificial Intelligence in COVID-19 Prevention, Diagnosis, Treatment and Management Decisions in China.
    Dong J; Wu H; Zhou D; Li K; Zhang Y; Ji H; Tong Z; Lou S; Liu Z
    J Med Syst; 2021 Jul; 45(9):84. PubMed ID: 34302549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.
    Zhou H; Ni WJ; Huang W; Wang Z; Cai M; Sun YC
    Front Immunol; 2022; 13():834942. PubMed ID: 35450063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19: a conundrum to decipher.
    Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics.
    Kumar V
    Int Immunopharmacol; 2020 Nov; 88():106980. PubMed ID: 33182073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options.
    Nazerian Y; Ghasemi M; Yassaghi Y; Nazerian A; Hashemi SM
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109428. PubMed ID: 36379152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.
    Chatterjee SK; Saha S; Munoz MNM
    Front Mol Biosci; 2020; 7():196. PubMed ID: 32850977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: a descriptive study.
    Chen Z; Deng X; Fang L; Sun K; Wu Y; Che T; Zou J; Cai J; Liu H; Wang Y; Wang T; Tian Y; Zheng N; Yan X; Sun R; Xu X; Zhou X; Ge S; Liang Y; Yi L; Yang J; Zhang J; Ajelli M; Yu H
    medRxiv; 2022 Jun; ():. PubMed ID: 35765564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.